Yarbrough J, Mansfield L E, Ting S
Ann Allergy. 1985 Jul;55(1):25-7.
Beta-adrenergic agonists in metered dose inhalers (MDIs) are used extensively in the treatment of asthma. Previously we reported that 23 of 1450 (1.6%) of our asthmatic patients experienced immediate bronchoconstriction after using MDI-albuterol. In this study we investigated immediate bronchoconstriction after use of MDI-metaproterenol and after placebo-inhaler with "inert ingredients" only. Results suggest that those patients who complained of chest tightness or lack of relief following the use of MDI beta-adrenergic agonists are having true bronchoconstriction. The bronchoconstrictive response is most likely caused by the propellants or the other inert ingredients contained in these MDIs.
定量吸入器(MDIs)中的β-肾上腺素能激动剂被广泛用于治疗哮喘。此前我们报告称,在1450名哮喘患者中,有23名(1.6%)在使用MDI-沙丁胺醇后出现了即刻支气管收缩。在本研究中,我们调查了使用MDI-间羟异丙肾上腺素后以及仅使用含“惰性成分”的安慰剂吸入器后的即刻支气管收缩情况。结果表明,那些在使用MDIβ-肾上腺素能激动剂后抱怨胸部发紧或未缓解的患者确实出现了支气管收缩。这种支气管收缩反应很可能是由这些MDIs中所含的推进剂或其他惰性成分引起的。